CTLA-4与PD-1/PD-L1免疫检查点抑制剂治疗子宫内膜癌新进展

Progress of CTLA-4 and PD-1/PD-L1 immune checkpoint inhibitors in the treatment of endometrial carcinoma

免疫检查点抑制剂(ICIs)是可调节免疫反应。细胞毒性T淋巴细胞相关抗原4 (CTLA-4)和程序性死亡受体1 (PD-1)/程序性死亡受体配体1 (PD-L1)对应的免疫检查点抑制剂已在临床抗肿瘤中展现出极大优势。免疫检查点抑制剂通过阻断免疫检查点通路,激活免疫细胞识别和杀伤的功能治疗子宫内膜癌,从而达到抗肿瘤效果,应用前景广阔。

Immune checkpoint inhibitors(ICIS)are a class of inhibitory molecules in the immune system that regulate immune responses.Cytotoxic T-lymphocyte-associated antigen 4(CTLA-4)and programmed death receptor 1(PD-1)/programmed cell death ligand 1(PD-L1)are immune checkpoint molecules,and their counterpart immune check-point inhibitors have exhibited great advantages in clinical anti-tumor research.Immune checkpoint inhibitors treat endo-metrial cancer by blocking immune checkpoint pathways,activating the function of immune cell recognition and killing,thus achieving anti-tumor effect,with promising application.